Levobupivacaine Altan Pharma (Levobupivacaine)

Levobupivacaine is employed in the management of pain and anesthesia across several clinical settings.

• Surgical anesthesia: produces profound loss of sensation for operative procedures.
• Post‑operative analgesia: extends pain relief after surgery to reduce opioid requirements.
• Obstetric analgesia: provides effective labor pain control while preserving maternal consciousness.

• Levobupivacaine reversibly blocks voltage‑gated sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. By stabilising the neuronal membrane, it prevents depolarisation and thus produces a reversible loss of sensory and motor function in the targeted region.

Levobupivacaine may cause a range of adverse reactions, most of which are dose‑ and site‑dependent.

Common Side Effects

• Injection site pain or irritation.
• Transient numbness or tingling in the blocked area.
• Mild hypotension.
• Nausea or vomiting.
• Headache.
• Metallic taste.

Serious or Rare Side Effects

• Central nervous system toxicity (e.g., seizures, altered consciousness).
• Cardiovascular toxicity (e.g., arrhythmias, cardiac arrest).
• Allergic reactions including rash or anaphylaxis.
• Persistent motor block.
• Methemoglobinemia.
• Spinal hematoma after neuraxial administration.

When using Levobupivacaine, clinicians should observe several safety measures.

• Patient assessment: evaluate cardiovascular and neurological status before administration.
• Dose limits: adhere to recommended maximum doses for each route.
• Monitoring: observe for signs of systemic toxicity during and after injection.
• Contraindications: avoid in patients with known hypersensitivity to amide local anesthetics.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Storage: Store at 2‑8°C: keep refrigerated, protect from light, do not freeze.

Levobupivacaine can interact with other agents that affect the nervous or cardiovascular systems.

Major Interactions (Avoid)

• Class I anti‑arrhythmic drugs (e.g., quinidine, procainamide): may potentiate cardiotoxicity.
• Other local anesthetics: increase risk of cumulative toxicity.
• CNS depressants (e.g., benzodiazepines, opioids): may exacerbate central nervous system depression.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask early signs of hypotension.
• Calcium channel blockers: could enhance negative inotropic effects.
• Diuretics: may alter plasma protein binding, affecting free drug levels.